These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 16118859

  • 1. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Sherry JH, Bechtel T.
    Neurology; 2005 Aug 23; 65(4):657-8; author reply 657-8. PubMed ID: 16118859
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH.
    Ann Pharmacother; 2012 May 23; 46(5):650-8. PubMed ID: 22550275
    [Abstract] [Full Text] [Related]

  • 9. More on high-dose busulfan and seizure prophylaxis.
    Tiberghien P, Flesch M, Paintaud G, Cahn JY.
    Bone Marrow Transplant; 1992 Feb 23; 9(2):147. PubMed ID: 1637404
    [No Abstract] [Full Text] [Related]

  • 10. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS.
    Neurology; 2008 Aug 12; 71(7):525-30. PubMed ID: 18695164
    [Abstract] [Full Text] [Related]

  • 11. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D, Aarons L, Ahmed IA.
    Arch Med Res; 2005 Aug 12; 36(1):49-53. PubMed ID: 15777995
    [Abstract] [Full Text] [Related]

  • 12. Paradoxical seizures in phenytoin toxicity.
    Chua HC, Venketasubramanian N, Tan CB, Tjia H.
    Singapore Med J; 1999 Apr 12; 40(4):276-7. PubMed ID: 10487084
    [Abstract] [Full Text] [Related]

  • 13. Generic anticonvulsant use in children: do we have evidence to recommend brand formulations?
    Hamiwka LD.
    Arch Neurol; 2009 Nov 12; 66(11):1417-8. PubMed ID: 19901177
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fosphenytoin facts.
    Chioffi SM, Lassiter TF, Scates AC, McLendon BM.
    Am J Nurs; 1999 Aug 12; 99(8):14. PubMed ID: 10456012
    [No Abstract] [Full Text] [Related]

  • 16. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape.
    Valodia P, Seymour MA, Kies BM, Folb PI.
    S Afr Med J; 1998 Jul 12; 88(7):873-5. PubMed ID: 9698715
    [Abstract] [Full Text] [Related]

  • 17. Is bioavailability altered in generic versus brand anticonvulsants?
    Jankovic SM, Ignjatovic Ristic D.
    Expert Opin Drug Metab Toxicol; 2015 Mar 12; 11(3):329-32. PubMed ID: 25440299
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
    Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ.
    Epilepsy Behav; 2008 Nov 12; 13(4):693-9. PubMed ID: 18589000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.